发布时间：2025-11-04 10:09 Findings Reinforce QDENGA’s Long-Term Safety Profile and Two-Dose Vaccination Schedule
QDENGA is the Longest-Studied Dengue Vaccine and the Only Approved for Use Regardless of Prior Disease Exposure
Takeda is Expanding Global Access to QDENGA in Partnership with National Immunization Programs, Private Payors and Public Health Coalitions, with 18.6 Million Doses Distributed in 11 Endemic Countries



OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3Tetravalent Immunization against Dengue Efficacy Study(TIDES) trial evaluating its dengue vaccine, QDENGA®▼(Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). These data, including an exploratory analysis of a booster dose, confirm the favorable benefit and risk profile of QDENGA and that the two-dose regimen provides sustained protection against dengue. This is consistent with its approved indications
=*=*=*=*=*=
当前为第1/21页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页